Octaplex is prothrombin complex concentrate (PCC) containing therapeutic and balanced levels of Factors II, VII, IX and X, as well as inibitory proteins C and S. It is indicated for treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex coagulation factors or in congenital deficiency factors II and X when purified specific coagulation factor products are not available. Octaplex has been shown to provide rapid INR reversal within 10 minutes, with a small volume (500 IU in 20 mL) and short infusion time.
Fibryga® is a highly purified and pathogen inactivated human fibrinogen concentrate and an effective and convenient treatment for fibrinogen deficiency. Fibryga® offers a number of benefits: concentration is standardised; it is stable at room temperature, can be reconstituted within minutes, and has a low infusion volume; there is no need for thawing or cross-matching blood type and it is double pathogen inactivated.
• Treatment of bleeding and perioperative prophylaxis in patients with congenital hypo or afibrinogenaemia with bleeding tendency.1-3
• Complementary therapy in the treatment of uncontrolled severe haemorrhage in patients with acquired fibrinogen deficiency.4
Fibryga® is presented in vials containing 1 g of fibrinogen as lyophilised powder for reconstitution with 50 mL sterile water for injection (WFI). After reconstitution, the solution provides approximately 20 mg/mL of human fibrinogen. For intravenous administration via infusion or injection.
Octagam is a human normal immunoglobulin (IVIg) that is indicated for replacement therapy in patients with primary immunodeficiency syndromes, myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and children with congenital AIDS and recurrent infections. It is also used in immunomodulation of idiopathic thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, in patients with Guillain Barré syndrome and Kawasaki disease. Another approved indication is for allogeneic bone marrow transplantation. Octagam has been used in more than 80 countries globally, which provides reassurance to both patients and physicians.
Octanate 500 IU contains human coagulation factor VIII, and is indicated for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). It is naturally stabilised and protected by VWF, and is highly purified and efficacious.
Albunorm is human albumin which is used for maintenance of colloid osmotic pressure, regulation of intravascular and extravascular fluid volume, with buffer effect and transport function in human plasma.